ORIGINAL ARTICLE

CrossMark

Clinical role of fludeoxyglucose (18F) positron emission tomography/computed tomography (^{18}F-FDG PET/CT) in patients with pancreatic neuroendocrine tumors

Takashi Matsumoto[1] · Hirohisa Okabe[1] · Yo-ichi Yamashita[1] · Toshihiko Yusa[1] · Rumi Itoyama[1] · Yosuke Nakao[1] · Takanobu Yamao[1] · Naoki Umzaki[1] · Masayo Tsukamoto[1] · Yuki Kitano[1] · Tatsunori Miyata[1] · Kota Arima[1] · Hidetoshi Nitta[1] · Hiromitsu Hayashi[1] · Katsunori Imai[1] · Akira Chikamoto[1] · Hideo Baba[1]

Abstract

Purposes Clinical predictive markers for the malignant potential of pancreatic neuroendocrine tumors (PNETs) are limited without histological investigation. We reported previously that a loss of the regular enhancement pattern in preoperative computed tomography (CT) was correlated with the malignant tumor phenotype. This study aimed to establish whether the metabolic aspect of the tumor evaluated by fludeoxyglucose (^{18}F) positron emission tomography/computed tomography ^{18}F-FDG PET/CT is associated with the tumor imaging characteristics and postoperative oncological outcome.

Methods Among 77 patients who underwent surgery with curative intent for a PNET at our institution between 2001 and 2017, 24 who received ^{18}F-FDG PET/CT before surgery were enrolled in this study. The clinical importance of the standardized uptake value (SUVmax) was investigated with regard to tumor progression and prognosis after curative surgery.

Results There were four (16%) patients with insulinoma. The mean tumor size was 17 mm and when the median value of the SUVmax ($=2.0$) was measured as the cut-off value, the SUVmax ≥ 2.0 group ($n = 12$) was associated with large tumor size ($p = 0.021$), high tumor grade ($p = 0.015$), and irregular pattern on CT ($p = 0.0055$). The SUVmax was not correlated with age, gender, whether the tumor was functioning or non-functioning, or lymph node metastasis. The SUVmax ≥ 2.0 group had significantly poorer disease-free survival (median, 3.5 vs 16.2 months; $p = 0.023$) and poorer overall survival (median, 8.8 vs 16.2 months; $p = 0.042$).

Conclusion An SUVmax ≥ 2.0 on ^{18}F-FDG PET/CT might be associated with higher malignant potential of PNETs.

Keywords Pancreatic neuroendocrine tumor · ^{18}F-FDG PET/CT · Irregular shape and enhancement pattern

Introduction

Pancreatic neuroendocrine tumors (PNETs) are the second most common primary pancreatic malignancy, accounting for 1–2% of newly diagnosed pancreatic tumors each year [1, 2]. The incidence of PNETs is 2.5–5 in 100,000 individuals per year worldwide and has increased rapidly, in line with developments in imaging modalities [3, 4].

Although there have been remarkable advances in the diagnosis and treatment of PNET, there has not been a comparable progression in the ability to predict disease progression and prognosis. Some reports have suggested prognostic factors for predicting survival and disease progression of PNET, including tumor size, whether the tumor is functioning or non-functioning, Ki67 index, distant metastases, and treatment modality, but these studies have been inconclusive about the non-invasive indicators of malignant potential [5, 6].

Positron emission tomography/computed tomography (PET/CT) using ^{18}F-fluorodeoxyglucose (^{18}F-FDG) has been shown to be valuable for initial staging and for detecting the recurrence of many tumor types including PNETs. ^{18}F-FDG PET/CT is a non-invasive imaging technique based on the principle of specific tissue metabolism [7, 8]. The prognostic value of ^{18}F-FDG PET/CT has been investigated for several cancers, such as non-small cell lung cancer [9], metastatic colorectal cancer [10, 11], and gastric cancer [12, 13].

✉ Hirohisa Okabe
    okabeh@kumamoto-u.ac.jp

Extended author information available on the last page of the article

We reported previously that the radiologic characteristics of PNET are associated with tumor progression [14]. In that report, the attenuation of enhancement and irregular-shaped expansion on enhanced CT were correlated with recurrence and poor prognosis after curative surgery. Based on this finding, we assumed that tumor progression under hypoxic conditions might be relevant to malignant characteristics. Previous reports have demonstrated an association between standardized uptake value (SUVmax) and the stage and metastatic status of PNETs [15, 16].

We conducted this study to clarify whether "irregular shape and enhancement pattern", which was defined in a previous report [14], is dependent on glucose metabolism; and the clinical significance of ^{18}F-FDG PET/CT for predicting the malignant potential of PNETs.

Patients and methods

Patients

Between April 2001 and October 2017, 77 patients with a preoperative diagnosis of PNET underwent curative pancreatic resection at the Department of Gastroenterological Surgery, Kumamoto University. Twenty-four of these patients received ^{18}F-FDG PET/CT preoperatively and were the subjects of this study. Tumors were evaluated preoperatively by different diagnostic imaging modalities, including endoscopic ultrasonography, abdominal CT, and magnetic resonance imaging (MRI). In patients with multiple tumors, the diameter of the largest tumor was measured. This study was approved by the Human Ethics Review Committee of the Graduate School of Medicine, Kumamoto University.

FDG/PET-CT

^{18}F-FDG PET/CT was performed by injecting 10–12 mCi of 18F-FDG after an overnight fast. The blood glucose level was measured just before tracer administration and was confirmed within 140 mg/ml. For quantitative analysis, the SUVmax was calculated at the sites of suspected tumor foci on CT scans. The positive uptake of FDG was defined as the focal uptake with a SUVmax of ≥ 2.0, which was the median value of this cohort.

Histological examination

Histological grading and staging were based on the World Health Organization (WHO) classification for PNET (2010) and the TNM classification of the Union for International Cancer Control (UICC) and European Neuroendocrine Tumor Society (ENETS). Histological examination routinely included hematoxylin and eosin staining, and additional staining with neuroendocrine markers (synaptophysin, chromogranin A). Tumor grade was determined by the mitotic count in ten high-power fields and by the percentage of tumor cells that were immunohistochemically Ki-67 positive.

Tumor shape and enhancement pattern on enhanced CT

The definition of tumor shape and enhancement characteristics were described previously [14]. Briefly, the tumor shape and enhancement characteristics were evaluated in the arterial or portal phase. Tumors with characteristics that met all of the following criteria were defined as having "regular tumor shape and enhancement"

1. A round or oval shape with a distinct or indistinct margin. For small tumors, obtaining robust contrast between the tumor and background pancreas is sometimes difficult.
2. Homogeneous tumor enhancement.
3. Enhancement is greater than that of the background pancreatic parenchyma. Tumors not meeting the criteria were defined as having "irregular shape and/or enhancement".

Statistical analysis

All p values were two sided. Qualitative variables were compared using χ^2 tests, and quantitative variables were compared using Wilcoxon tests. For overall survival (OS) and relapse-free survival (RFS), we used the log-rank test and the Kaplan–Meier method. Commercial software (JMP Version 10®, SAS Institute, Cary, NC, USA) was used for all statistical analyses, with $p < 0.05$ defined as significant.

Results

Patients' characteristics

The median age was 60 (17–81) years. Nineteen patients had non-functioning tumors (79.2%), four had insulinomas (16.7%), and one had a glucagonoma (4.2%). One patient (4.2%) had multiple endocrine neoplasia 1 (MEN1) disease. All patients underwent pancreatic surgery with curative intent. Two patients (8.4%) were found to have liver metastases at surgery. Table 1 gives details of the surgical procedure, tumor size, lymph node status and pathological findings. The median follow-up for the 24 patients who were still alive at the time of last follow-up was 12 (1–101) months. Four patients (16.7%) died during follow-up: one (4.2%) of advanced esophageal cancer and three of liver metastases.

Table 1 Background characteristics of the patients with pancreatic neuroendocrine tumors (PNETs)

Clinicopathological factors	Patient number $n = 24$
Age[a] (years)	60 [17–81]
Male sex[a]	13 (54%)
Tumor size[a] (mm)	17 [5–70]
SUVmax[a]	2.0 [0–13.7]
Histological grade[b] (grade 1/2/3)	14 (58%)/7 (29%)/3 (13%)
TMN staging[c] (I/II/III/VI)	14 (58%)/6 (25%)/2 (8%)/2 (8%)
dTumor type	
Non-functioning	19 (79%)
Insulinoma	4 (17%)
Glucagonoma	1 (4%)
Operation procedure	
Pancreaticoduodenectomy	6 (22%)
Distal pancreatectomy	14 (25%)
Middle pancreatectomy	1 (4%)
Enucleation	3 (13%)
Synchronous liver metastasis	2 (8%)
Lymph node metastasis	4 (17%)
Capsular invasion	9 (38%)
Irregular shaped and/or enhancement tumor	12 (50%)

[a]Results are expressed as the median [range] or as an absolute number

[b]Histological grade is defined by the WHO classification 2010

[c]TNM staging is according to the 7th edition of the TNM classification

Recurrence was found in six patients after surgery. All six had liver metastases, one also had lymph node metastasis, and one also had lung metastasis.

Relationship between clinical variables and the SUVmax

With the median SUVmax ($n = 2.0$) defined as the cut-off value, an SUVmax ≥ 2.0 was significantly correlated with clinical variables relevant to disease progression, such as large tumor size ≥ 3.0 cm ($p = 0.0255$), histological grade 2/3 ($p = 0.0066$), and pathological capsular invasion ($p = 0.0066$) (Table 2). There was a high correlation between tumor size and SUVmax ($r = 0.553$, $p = 0.0204$; Fig. 1a). Grade 1 tumors had a significantly lower correlation with an SUVmax ≥ 2.0 than grade 2 and grade 3 tumors ($p = 0.0204$ and 0.0258, respectively; Fig. 1b). An SUVmax ≥ 2.0 was significantly correlated with poor RFS and poor OS ($p = 0.0255$ and 0.0424, respectively; Fig. 2a, b).

Relationship between radiological features and the SUVmax

Based on our previous investigation, patients were divided into a regular shape and enhancement pattern group (regular type, $n = 12$) and an irregular shape and/or enhancement

Table 2 Relationship between the standardized uptake value (SUV) max and clinicopathological factors

Clinicopathological factors	SUVmax		p value
	≥ 2.0 ($n = 12$)	< 2.0 ($n = 12$)	
Age[a] (years) median [range]	58 [18–76]	65 [17–81]	0.3856
Gender male	6 (50.0%)	7 (58.3%)	0.6820
Tumor size[a] (mm)	7.3 [5–23]	10 [5–70]	0.0255
Number of tumor ≥ 2	4 (33%)	6 (50%)	0.4064
Histological grade (grades 2 and 3)	7 (58%)	1 (8%)	0.0066
TMN stages III and IV	3 (25%)	1 (8%)	0.5901
Synchronous liver metastasis	0	2 (17%)	0.4783
Pathological capsular invasion	7 (58%)	1 (8%)	0.0066
Concomitant lymph node metastasis	2 (17%)	1 (8%)	0.5337
Non-functioning tumor	10 (83%)	9 (75%)	0.6143
Irregular type on CT	9 (75%)	3 (25%)	0.0122

[a]Results are expressed as the median [range] or as an absolute number

pattern group (irregular type, $n = 12$). Figure 3a presents typical cases of PNET. The regular type showed a low SUVmax, whereas the irregular type showed high SUVmax. The SUVmax was significantly higher in the irregular type

Fig. 1 Relationship between oncological outcome and the standardized uptake value (SUV) max. **a** Correlation between the tumor size and SUVmax was found. R, correlation coefficient. **b** Correlation between the histological tumor grade and the SUVmax by Steel–Dwass test was evident


Fig. 2 Recurrence and prognosis based on the SUVmax. Kaplan–Meier curve of relapse-free survival (**a**) and overall survival (**b**) of the SUV max ≥ 2.0 group (n = 12) versus the SUVmax < 2.0 group (n = 12) after surgery with curative intent


Fig. 3 Consistency of imaging characteristics determined by enhanced computed tomography (CT) and fludeoxyglucose (18F) positron emission tomography/CT ([18F]-FDG PET/CT). **a** Repre-sentative image of enhanced CT and [18F]-FDG PET/CT in regular and irregular tumors. **b** Preoperative SUVmax of the regular tumor and irregular tumor groups by the Wilcoxon test

group than in the regular type group (mean 4.34 vs 1.23; $p = 0.0033$; Fig. 3b).

Discussion

The results of this study suggest that the SUVmax is associated with tumor progression in patients with PNET. The 2010 WHO guidelines recommend assessment of the malignant potential of PNET by tumor size and histological grade, which require invasive investigation. A previous study suggested that the histological grade of PNET obtained by fine-needle aspiration was inconsistent with that obtained from resected specimens in 3 of 22 patients [17]. A non-invasive biomarker that would enable us to assess malignant potential and monitor the treatment effect is still being sought. Of note, the SUVmax is significantly lower in histological grade 1 PNET than in grade 2 or grade 3 PNET and is highly correlated with tumor size. This suggests that a high SUVmax in ^{18}F-FDG PET/CT could be a non-invasive predictor of malignant potential.

Although few investigations have focused on the role of ^{18}F-FDG PET/CT in patients with PNET, a previous study showed that a hypoxic condition, assessed by enhanced CT, was correlated with recurrence and poor prognosis. This type of hypoxic condition is consistent with the increase in the SUVmax value in the current study. Cancers exhibit altered glucose metabolism, defined as the Warburg effect, and in some cancers, the regulators are reported to be a hypoxia-inducible factor (HIF) and c-Myc [18]. Whole genome analysis revealed that there was a subgroup associated with hypoxia and HIF signaling in patients with PNET [19]. Transcriptomic analysis of both a mouse model of PNET and human PNET revealed that a metastasis-like primary subtype, one of three major subtypes, had a remarkably high number of Ki67 + cells and a low number of CD31 + cells [20]. Patients with small tumors do not seem to have this altered glucose metabolism, which accompanies an increase in the size of the tumor. It is assumed that the oncogenic switch that induces the Warburg effect does not occur at the beginning of tumorigenesis, but later in tumor development. Because the number of patients in the current study was limited, studies with a larger patient sample are needed to confirm the clinical outcomes.

We analyzed the current cohort by the SUVmax and established that the cut-off of 2.0 was useful for discriminating aggressive tumors from less aggressive ones. Previous research suggests that the metabolic tumor volume measured by volumetric analysis with ^{18}F-FDG PET/CT can predict the prognosis of patients with PNET [15]. In the previous research, the mean tumor size was 31 mm and the median SUVmax value was 4.0, whereas in our cohort, the mean tumor size was 17 mm and the median SUVmax was 2.0. We

assume that our cohort included more patients with small and non-metastatic tumors, resulting in good correlation of the SUVmax and disease progression. Thus, metabolic tumor volume as suggested by the previous investigation might be useful to predict their prognosis of patients with advanced PNET.

Four of our patients with small tumors of < 2.0 cm had an SUVmax of ≥ 2.0. Two patients with hereditary diseases, including Hippel–Lindau disease and MEN1, had a 10-mm tumor with an SUVmax of 5.2 and recurrence in the remnant pancreas. An irregular pattern on enhanced CT was not seen in any of the patients, which suggests that ^{18}F-FDG PET/CT might play a clinical role, even in patients with small tumors < 2.0 cm in diameter and a regular shape/enhancement pattern on CT.

In conclusion, SUVmax is correlated with radiologic features as well as tumor progression in patients with PNET. An SUVmax ≥ 2.0 in ^{18}F-FDG PET/CT might be useful for assessing the malignant potential of PNET.

Compliance with ethical standards

References

1. Hill JS, McPhee JT, McDade TP, Zhou Z, Sullivan ME, Whalen GF, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer. 2009;115:741–51.
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.
3. Fitzgerald TL, Hickner ZJ, Schmitz M, Kort EJ. Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry. Pancreas. 2008;37:134–8.
4. Keutgen XM, Nilubol N, Kebebew E. Malignant-functioning neuroendocrine tumors of the pancreas: A survival analysis. Surgery. 2016;159:1382–9.
5. Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43:422–7.
6. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14:7798–803.
7. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am. 2001;39:883–917.
8. Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med. 2002;32:35–46.
9. Kwon W, Howard BA, Herndon JE, Patz EF. FDG uptake on positron emission tomography correlates with survival and time to recurrence in patients with stage i non-small-cell lung cancer. J Thorac Oncol. 2015;10:897–902.

10. Engelmann BE, Loft A, Kjaer A, Nielsen HJ, Gerds TA, Benzon EV, et al. Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer. Oncologist. 2014;19:164–72.
11. Shim JR, Lee SD, Han SS, Lee SJ, Lee DE, Kim SK, et al. Prognostic significance of (18)F-FDG PET/CT in patients with colorectal cancer liver metastases after hepatectomy. Europ J Surg Oncol. 2018;44:670–6.
12. Chung HW, Lee EJ, Cho YH, Yoon SY, So Y, Kim SY, et al. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma. J Cancer Res Clin Oncol. 2010;136:1929–35.
13. Song BI, Kim HW, Won KS, Ryu SW, Sohn SS, Kang YN. Preoperative standardized uptake value of metastatic lymph nodes measured by 18F-FDG PET/CT improves the prediction of prognosis in gastric cancer. Medicine. 2015;94:e1037.
14. Okabe H, Hashimoto D, Chikamoto A, Yoshida M, Taki K, Arima K, et al. Shape and enhancement characteristics of pancreatic neuroendocrine tumor on preoperative contrast-enhanced computed tomography may be prognostic indicators. Ann Surg Oncol. 2017;24:1399–405.
15. Kim HS, Choi JY, Choi DW, Lim HY, Lee JH, Hong SP, et al. Prognostic value of volume-based metabolic parameters measured by (18)F-FDG PET/CT of pancreatic neuroendocrine tumors. Nucl Med Mol Imaging. 2014;48:180–6.
16. Masui T, Doi R, Ito T, Kami K, Ogawa K, Harada D, et al. Diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with reference to the World Health Organization classification. Oncol Letters. 2010;1:155–9.
17. Farrell JM, Pang JC, Kim GE, Tabatabai ZL. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria. Cancer Cytopathol. 2014;122:770–8.
18. Sawayama H, Ishimoto T, Sugihara H, Miyanari N, Miyamoto Y, Baba Y, et al. Clinical impact of the Warburg effect in gastrointestinal cancer (review). Int J Oncol. 2014;45:1345–54.
19. Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543:65–71.
20. Sadanandam A, Wullschleger S, Lyssiotis CA, Grotzinger C, Barbi S, Bersani S, et al. A cross-species analysis in pancreatic neuroendocrine tumors reveals molecular subtypes with distinctive clinical, metastatic, developmental, and metabolic characteristics. Cancer Disc. 2015;5:1296–313.

Affiliations

Takashi Matsumoto[1] · Hirohisa Okabe[1] · Yo-ichi Yamashita[1] · Toshihiko Yusa[1] · Rumi Itoyama[1] · Yosuke Nakao[1] · Takanobu Yamao[1] · Naoki Umzaki[1] · Masayo Tsukamoto[1] · Yuki Kitano[1] · Tatsunori Miyata[1] · Kota Arima[1] · Hidetoshi Nitta[1] · Hiromitsu Hayashi[1] · Katsunori Imai[1] · Akira Chikamoto[1] · Hideo Baba[1]

Takashi Matsumoto
rowingrowing1989@gmail.com

Yo-ichi Yamashita
y-yama@kumamoto-u.ac.jp

Toshihiko Yusa
toshihiko.yusa@gmail.com

Rumi Itoyama
itoyama_rumi@yahoo.co.jp

Yosuke Nakao
yousuke_nmbb@yahoo.co.jp

Takanobu Yamao
i_am_kida7172205@yahoo.co.jp

Naoki Umzaki
bwcnh386@yahoo.co.jp

Masayo Tsukamoto
masayobychance13@yahoo.co.jp

Yuki Kitano
beat11100411@yahoo.co.jp

Tatsunori Miyata
tatsunori_miyata@yahoo.co.jp

Kota Arima
kota84115@gmail.com

Hidetoshi Nitta
hnitta5085@gmail.com

Hiromitsu Hayashi
h.hayashi13@gmail.com

Katsunori Imai
katsuimai@hotmail.com

Akira Chikamoto
achikamoto@fc.kuh.kumamoto-u.ac.jp

Hideo Baba
hdobaba@kumamoto-u.ac.jp

1 Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-Ku, Kumamoto 860-8556, Japan